Where Gossamer Bio Stands With Analysts
Analysts have provided the following ratings for Gossamer Bio (NASDAQ:GOSS) within the last quarter:
Barclays Maintains Overweight on Gossamer Bio, Lowers Price Target to $12
Barclays analyst Carter Gould maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $18 to $12.
Raymond James Initiates Coverage On Gossamer Bio with Outperform Rating, Announces Price Target of $19
Raymond James analyst Timur Ivannikov initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $19.
UBS Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $19
UBS analyst Eliana Merle initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and announces Price Target of $19.
Recap: Gossamer Bio Q4 Earnings
Gossamer Bio (NASDAQ:GOSS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
Gossamer Bio reported in-line EPS of $-0.74 versus an estimate of $-0.74.
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell
• Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million.
SVB Leerink Maintains Outperform on Gossamer Bio, Raises Price Target to $16
SVB Leerink analyst Joseph Schwartz maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and raises the price target from $15 to $16.